Home Online Features SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
Hand-out
Press Releases
SFA Therapeutics, Inc.  
March 7, 2025

SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis

Subjects demonstrated statistically significant improvements in Psoriasis Area and Severity Index (PASI) and Investigator Global Assessment (IGA) scores

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social